Sign In
Buy BDX
$145.61
+1.18 (+0.82%)
At Close: Jun 03, 2026
BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research
06:45am, Monday, 14'th Oct 2024
Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing FRANKLIN LAKES, N.J. , Oct. 14, 2024 /PRNewswire/ --�
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Friday, 11'th Oct 2024
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
10:46am, Friday, 11'th Oct 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
04:15pm, Thursday, 10'th Oct 2024
Announces Dates for Fiscal 2025 Quarterly Earnings Webcasts FRANKLIN LAKES, N.J. , Oct. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology com
Undervalued Dividend Kings: October 2024
09:00am, Tuesday, 08'th Oct 2024
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for pote
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock
10:56am, Monday, 07'th Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now
01:10pm, Thursday, 03'rd Oct 2024
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation
05:00pm, Wednesday, 02'nd Oct 2024
No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and w
My Best Dividend Aristocrats For October 2024
09:19am, Friday, 27'th Sep 2024
The ProShares S&P 500 Dividend Aristocrats ETF extends it's good form in the second half of 2024, adding a gain of 3.69% in August. I present 3 strategies that can theoretically beat the dividend aris
New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion
06:50am, Thursday, 26'th Sep 2024
FRANKLIN LAKES, N.J. , Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its adv
Why Matrix CIO is chasing Becton Dickinson and US Bancorp
03:08pm, Tuesday, 24'th Sep 2024
David Katz, chief investment officer at Matrix Asset Advisors, joins 'The Exchange' to discuss his picks in the markets, how to position for the future, and more.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
09:35am, Friday, 20'th Sep 2024
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics
12:16pm, Thursday, 19'th Sep 2024
BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.
BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
06:50am, Wednesday, 18'th Sep 2024
LE PONT-DE-CLAIX, France , Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopa
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
10:03am, Friday, 13'th Sep 2024
I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position
